Neil A. Waters

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry Data.

A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry Data.

Journal: PharmacoEconomics
Published: April 28, 2025

Blood Transfusion Practices in Intensive Care: A Prospective Observational Binational Study.

Blood Transfusion Practices in Intensive Care: A Prospective Observational Binational Study.

Journal: Critical care explorations
Published: February 21, 2025

Economic burden of sickle cell disease in Australia.

Economic burden of sickle cell disease in Australia.

Journal: Internal medicine journal
Published: July 10, 2024

Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry.

Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry.

Journal: PloS one
Published: May 30, 2024

Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry.

Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry.

Journal: Leukemia & lymphoma
Published: February 20, 2024

Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials.

Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials.

Journal: BMJ open
Published: January 18, 2024

The establishment of a multiple myeloma clinical registry in the Asia-Pacific region: The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR).

The establishment of a multiple myeloma clinical registry in the Asia-Pacific region: The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR).

Journal: BMC medical research methodology
Published: December 06, 2023

Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era.

Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era.

Journal: Internal medicine journal
Published: November 15, 2023

Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies.

Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies.

Journal: Blood advances
Published: October 30, 2023

The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry.

The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry.

Journal: Best practice & research. Clinical haematology
Published: August 14, 2023

Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy.

Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy.

Journal: Blood advances
Published: July 17, 2023

Sickle cell disease in Australia: a snapshot from the Australian Haemoglobinopathy Registry.

Sickle cell disease in Australia: a snapshot from the Australian Haemoglobinopathy Registry.

Journal: Internal medicine journal
Published: March 23, 2023
Showing 1-12 of 17

Last Updated: 09/26/2026